Table 7.

Asthma Research Content Perceived as Useful by End Users

	End User Type*
	BI	CL	ED	RG
Intervention (including environmental regulation) and Remediation
Descriptions and analyses of the social and physical environment			√	√
Triggers and causes of exacerbation		√	√
Environmental controls		√	√	√
Environmental exposures	√	√	√	√
Occupational exposures		√	√	√
Baseline burden in typical home; what is typical and what is high in terms of allergens			√	√
Connections between clinic data and home data			√	√
Issues in building science that affect asthma			√	√
Assessment and remediation of the health effects of contaminants			√	√
Intervention effectiveness			√
Social and behavioral influences on case management			√
Teaching or learning approaches			√
Environmental justice			√	√
Research from all phases in the drug development cycle to support regulation and standard setting				√
New Drug Development and Regulation
Clinical applications of drugs	√	√	√	√
Effects of medication	√	√	√	√
New medications	√	√	√	√
Therapeutic product information (e.g., tolerance of therapeutics by patients, adverse effects)	√	√	√	√
Changing patterns in asthma prevalence	√
Pharmacogenetics	√	√	√	√
Clinical Practice
Latest advances in research and implications for practice	√	√	√	√
Etiology of severe asthma and implications for asthma management		√	√
Viral etiologies of asthma and implications for asthma management	√	√	√
Gene-environment interactions		√	√	√
Best practices for managing asthma	√	√	√
Issues in treatment	√	√	√
Issues in adherence	√	√	√
Interactions between different care providers		√	√

^*Business and Industry [BI], Clinical [CL], Education and Advocacy [ED], Regulators [RG]

√ Indicates that at least one end user in this category identified the research content as useful.